KaloBios Pharmaceuticals Inc's ( KBIO ) share price has entered into oversold territory with an RSI value of 24.4. The Zacks Consensus Estimate for KaloBios for the full year period has improved 8 cents over the past two months to -$1.40 per share. Currently, KaloBios has a Zacks Rank #2 (Buy), suggesting that now might be a good time to get in on ( KBIO ) after its recent drop.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.